However, a significant upregulation in BAX expression level was observed in hepatic cancer cell lines treated with doxorubicin (200 μm) or sitagliptin (IC50: 89 μM; or IC35; 62.5 μM) to reach 4.23, 4.15, and 2.72 folds, respectively, as compared to the untreated HepG2 cells. Here, BAX is linked to liver cancer.